ReMEDyX when the and since is have our the that a the first challenging event. participant participant dosed clinical a first I'm crucial trial. everyone. Good Enrolling pleased we with announcement safety for off milestone morning, restart hold coming of our particularly the recent
dose is was our the demonstrating IV this with observed the no that previously the there hypotension. first of of restart.
The appropriate results positive be DMXXX and and we often dosed the was some on we reluctance transient higher inadvertent hypotension, from Ic hypotension the to cause trial participant recognize Phase with enroll resolved quickly, very dose despite Although who not does feedback investigator to observed the clearly
However, know to investigators participant Success received positive have enroll and safety a participants. we that success, begets or not optimistic drug placebo. we are more whether DMXXX, will first with their experience the them encouraging do other similar participant dosing
to where to either care to emphasize eligible want of option. have every treatment these standard receive mechanical and I that TPA has patients are treatment, stroke patient a future no see any a Investigators want treatment or alternative thrombectomy. not
So as we accrue we more expect quickly. momentum build safety data, to
From the discussions first key a meaningful to sample with them, size. sites, represents enrolling be point inflection this will a participants, XX believe we
will monthly the competition between sites. we We will keep sites our also our and newsletter abreast participant enrollment, attempt of study an facilitate send to future, out in a in active some friendly
Tampa General management Now with these discuss of have Scott Principal Kasner, site let Hospital, our of software orders pharmacy major processing activating activation. are the of In work which University common activated. National Investigator, we sites and sites We large Pennsylvania sites the me coordination some through X of a sites, sites, stroke associated individual center. the X Dr. specifics of currently to through learned X investigational these enable issue, had to we drug a platform.
positioned resolve participants. for to the sites to are potential and X these with closely now screen issue, both worked We
how just enhance we without experience practices like their closely participants all internal operations going activation queue one and systems working sites with actively their ensure that avoid drug site in to are of management site immediately platform We prior investigational can they fully interruption. to sites example at learned so forward. to is activation, best screening apply begin This pharmacy similar other are delays the operational all for from
of While activation slightly with behind in and be short-term major of activated this we bolus majority that year sites sites a will we are anticipate still U.S. targets, the our QX QX.
increasing With beyond high-quality initially level the The number the target considering the high are sites, of focusing considered stroke key on XX of enrollers. current sites we U.S. sites are planned. interest only is from now that quality
for trial U.S. many to These join and coming hospitals Importantly, major contributors working have is of the largest are the months. recent are trials, stroke now which to sites in enrolling start-up been stage our the encouraging study. our stroke in
involvement also to drive also competition their per sites rate. study a could contribute among that anticipate and We enrollment higher site
and particular, speaks the action of of to of mechanism differentiated cerebral We potential selectively increasing flow. in endorsement also our believe DMXXX their blood
U.S., the the are have progressing and identified In we X Canadian things Stroke official of finalizing Canada, for Canada. from sites Consortium, regulatory well. our with submissions Health are quality Outside support
sites We Alliance of the of endorsement protocol, formal and filing recently regulatory expect a of response end around our The we Australian June. study its provided Stroke are activities. in initiating process has the selecting and
network. as many of same engaged strengthen we as work team. ReMEDyX we to excited in sites the with announced new work to the of execute internally Rebekah progress DiaMedica also am recommended our and clinical lead believe on to has both January operations report plan initially addition a to at with the activation. multiple our We is year, continue highly joined I we operations, as made which by with and vendors, streamlining VP trials. as me and trial we our momentum centers joined in the third clinical externally Rebekah in of consultant site Earlier well will Fries our this our Rebekah This Operations. which to already Clinical that building has company substantial
personnel of clinical These and prior Rebekah are our also at mentioned additions experienced global with operations I both previously X companies. support additional the earlier worked The to trial. important expansion
call over to back I will turn Rick. now the
